DOI:
10.1055/s-00044881
Journal of Laboratory Physicians
LinksClose Window
References
Schmid P, Rugo HS, Adams S. et al; IMpassion130 Investigators.
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol 2020;
21 (01) 44-59
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.